Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)

7.50
Delayed Data
As of Jul 29
 -0.35 / -4.46%
Today’s Change
5.25
Today|||52-Week Range
78.05
-39.12%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$29.5M

Company Description

Madrigal Pharmaceuticals, Inc. develops novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). It offers MGL-3196, an orally administered, small-molecule liver-directed ß-selective THR agonist with high liver uptake for the treatment of NASH and dyslipidemia or hypercholesterolemia including in heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH). The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Contact Information

Madrigal Pharmaceuticals, Inc.
500 Office Center Drive
Fort Washington Pennsylvania 19034
P:(610) 527-6790
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Paul A. FriedmanChairman, President & Chief Executive Officer
Marc R. SchneebaumChief Financial Officer & Senior Vice President
Rebecca A. TaubClass II Director & Chief Medical Officer
Edward ChiangHead-Clinical Operations